Caris Life Sciences, Inc. (CAI)Healthcare | Biotechnology | Irving, United States | NasdaqGS
30.26 USD
+0.72
(2.455%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 30.26 |
Hot Take ↕ | Oct. 10, 2026, 9:32 a.m. EDT
The core story here is a biotech company with a fortress balance sheet and accelerating revenue growth that is currently trapped in a 'value trap' narrative. Fundamentally, the business is healthy: revenue is up 45%, margins are expanding, and the company holds significant cash against manageable debt. The stock trades at a reasonable multiple relative to sales, yet the market refuses to grant it a premium, likely due to the inherent binary risk of oncology trials and a fear of future earnings misses. The recent price action shows a struggle to break past the 50-day average, indicating institutional hesitation despite the positive fundamentals. The options data confirms this impasse. Traders are not betting on a smooth recovery; they are hedging against a potential collapse while keeping a small sliver of hope for a moonshot. This disconnect creates a frustrating environment for investors who want certainty. While the long-term thesis is sound given the growth trajectory and financial strength, the short-term path is obscured by uncertainty. Until the market resolves whether this is a deep value opportunity or a value trap waiting to fall, the investment case remains neutral-to-slightly-positive, but not a high-conviction buy. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.420142 |
| AutoETS | 0.420142 |
| MSTL | 0.421564 |
| AutoTheta | 0.456498 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 6.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.172 |
| Excess Kurtosis | -0.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 76.454 |
| Revenue per Share | 3.492 |
| Market Cap | 8,549,917,696 |
| Trailing P/E | 17.90 |
| Forward P/E | 81.35 |
| Profit Margins | 10.62% |
| Website | https://www.carislifesciences.com |
As of Oct. 10, 2026, 9:32 a.m. EDT: Speculators are positioning for volatility rather than a clear directional breakout. In the near term (October 2026), there is heavy open interest in out-of-the-money puts relative to calls, suggesting a hedge against downside or a bet on stagnation. However, looking further out to early 2027, the landscape flips dramatically: massive open interest accumulates in deep in-the-money puts (strikes 15, 17.5, 20), while call activity shifts to very high strikes (40). This 'long gamma' structure at extreme levels implies the market is pricing in a binary event—either a massive crash to the lows or a speculative rocket ship to the highs—rather than a steady grind. The lack of significant call volume at moderate upside targets suggests skepticism about a controlled rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.052310646 |
| Address1 | 750 West John Carpenter Freeway |
| Address2 | Suite 800 |
| All Time High | 42.5 |
| All Time Low | 14.19 |
| Ask | 32.56 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 4,254,440 |
| Average Daily Volume3 Month | 4,995,289 |
| Average Volume | 4,995,289 |
| Average Volume10Days | 4,254,440 |
| Bid | 27.76 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 2.094 |
| City | Irving |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 30.255 |
| Current Ratio | 5.526 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 31.53 |
| Day Low | 29.065 |
| Debt To Equity | 76.454 |
| Display Name | Caris Life Sciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 174,024,992 |
| Ebitda Margins | 0.17584999 |
| Enterprise To Ebitda | 45.995 |
| Enterprise To Revenue | 8.088 |
| Enterprise Value | 8,004,322,816 |
| Eps Current Year | 0.13801 |
| Eps Forward | 0.37192 |
| Eps Trailing Twelve Months | 1.69 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 866 479 4925 |
| Fifty Day Average | 26.2713 |
| Fifty Day Average Change | 3.9836998 |
| Fifty Day Average Change Percent | 0.15163696 |
| Fifty Two Week Change Percent | -5.231065 |
| Fifty Two Week High | 33.65 |
| Fifty Two Week High Change | -3.3950024 |
| Fifty Two Week High Change Percent | -0.1008916 |
| Fifty Two Week Low | 14.19 |
| Fifty Two Week Low Change | 16.064999 |
| Fifty Two Week Low Change Percent | 1.1321353 |
| Fifty Two Week Range | 14.19 - 33.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,750,253,400,000 |
| Float Shares | 134,865,727 |
| Forward Eps | 0.37192 |
| Forward P E | 81.34814 |
| Free Cashflow | 63,262,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,846 |
| Fullday Change | 0.7249985 |
| Fullday Change Percent | 2.455125 |
| Fullday Price | 30.255 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.69848996 |
| Gross Profits | 691,233,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.48792 |
| Held Percent Institutions | 0.56588 |
| Implied Shares Outstanding | 282,595,186 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-06-18 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas. |
| Long Name | Caris Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 8,549,917,696 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_285971879 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 105,135,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,945,550,612 |
| Number Of Analyst Opinions | 13 |
| Open | 29.23 |
| Operating Cashflow | 168,558,000 |
| Operating Margins | 0.1021 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 866 771 8946 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 30.255 |
| Post Market Time | 1,792,011,206 |
| Previous Close | 29.53 |
| Price Eps Current Year | 219.22325 |
| Price Hint | 2 |
| Price To Book | 14.448423 |
| Price To Sales Trailing12 Months | 8.639728 |
| Profit Margins | 0.10624 |
| Quick Ratio | 4.754 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.64286 |
| Region | US |
| Regular Market Change | 0.7249985 |
| Regular Market Change Percent | 2.455125 |
| Regular Market Day High | 31.53 |
| Regular Market Day Low | 29.065 |
| Regular Market Day Range | 29.065 - 31.53 |
| Regular Market Open | 29.23 |
| Regular Market Previous Close | 29.53 |
| Regular Market Price | 30.255 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 4,346,176 |
| Return On Assets | 0.08769 |
| Return On Equity | 0.20129 |
| Revenue Growth | 0.454 |
| Revenue Per Share | 3.492 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 282,595,186 |
| Shares Percent Shares Out | 0.049200002 |
| Shares Short | 13,891,975 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 13,684,372 |
| Short Name | Caris Life Sciences, Inc. |
| Short Percent Of Float | 0.12060001 |
| Short Ratio | 2.68 |
| Source Interval | 15 |
| State | TX |
| Symbol | CAI |
| Target High Price | 38.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 31.61538 |
| Target Median Price | 33.0 |
| Total Cash | 793,115,008 |
| Total Cash Per Share | 2.807 |
| Total Debt | 452,401,984 |
| Total Revenue | 989,604,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.69 |
| Trailing P E | 17.902367 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.2438 |
| Two Hundred Day Average Change | 9.0112 |
| Two Hundred Day Average Change Percent | 0.42418024 |
| Type Disp | Equity |
| Volume | 4,346,176 |
| Website | https://www.carislifesciences.com |
| Zip | 75,039 |